Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 20206498)

1.

Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis.

Pylväs M, Puistola U, Kauppila S, Soini Y, Karihtala P.

Eur J Cancer. 2010 Jun;46(9):1661-7. doi: 10.1016/j.ejca.2010.02.006. Epub 2010 Mar 4.

PMID:
20206498
2.

DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma.

Karihtala P, Soini Y, Vaskivuo L, Bloigu R, Puistola U.

Int J Gynecol Cancer. 2009 Aug;19(6):1047-51. doi: 10.1111/IGC.0b013e3181ad0f0d.

PMID:
19820366
3.

Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.

Fauvet R, Dufournet C, Poncelet C, Uzan C, Hugol D, Daraï E.

J Surg Oncol. 2005 Dec 15;92(4):337-43.

PMID:
16299808
4.

Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.

Wang C, Horiuchi A, Imai T, Ohira S, Itoh K, Nikaido T, Katsuyama Y, Konishi I.

J Pathol. 2004 Feb;202(2):215-23.

PMID:
14743504
5.

Increasing oxidative damage and loss of mismatch repair enzymes during breast carcinogenesis.

Karihtala P, Winqvist R, Syväoja JE, Kinnula VL, Soini Y.

Eur J Cancer. 2006 Oct;42(15):2653-9. Epub 2006 Sep 22.

PMID:
16996262
6.

Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.

Palazzo JP, Monzon F, Burke M, Hyslop T, Dunton C, Barusevicius A, Capuzzi D, Kovatich AJ.

Hum Pathol. 2000 Jun;31(6):698-704.

PMID:
10872663
7.

8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma.

Soini Y, Haapasaari KM, Vaarala MH, Turpeenniemi-Hujanen T, Kärjä V, Karihtala P.

Int J Clin Exp Pathol. 2011 Mar;4(3):267-75. Epub 2011 Mar 2.

8.

Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.

Tan Y, Sinniah R, Bay BH, Singh G.

J Pathol. 1999 Sep;189(1):60-5.

PMID:
10451489
9.

[Expression of the cdx2 gene in benign intestinal-type mucinous ovarian tumors].

Gaggero G, Sola S, Mora M, Fulcheri E.

Pathologica. 2003 Aug;95(4):185-91. Italian.

PMID:
14577202
10.

Expression of apoptosis-related proteins in endometriomas and benign and malignant ovarian tumours.

Fauvet R, Poncelet C, Hugol D, Lavaur A, Feldmann G, Daraï E.

Virchows Arch. 2003 Jul;443(1):38-43. Epub 2003 May 20.

PMID:
12756564
11.

Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma.

Chung KH, Lee DH, Kim Y, Kim TH, Huh JH, Chung SG, Lee S, Lee C, Ko JJ, An HJ.

J Proteome Res. 2010 Jan;9(1):451-7. doi: 10.1021/pr900811x.

PMID:
19902980
12.

Borderline ovarian tumours: retrospective analysis of twenty-one cases.

Saygili U, Uslu T, Erten O, Doğan E.

Eur J Gynaecol Oncol. 1998;19(2):182-5.

PMID:
9611063
13.

Cell proliferation activity unrelated to COX-2 expression in ovarian tumors.

Yoshida A, Sarian LO, Andrade LA, Pignataro F, Pinto GA, Derchain SF.

Int J Gynecol Cancer. 2007 May-Jun;17(3):607-14.

PMID:
17504375
14.

Mac-2 binding protein and galectin-3 expression in mucinous tumours of the ovary: an annealing control primer system and immunohistochemical study.

Lee JH, Zhang X, Shin BK, Lee ES, Kim I.

Pathology. 2009;41(3):229-33. doi: 10.1080/00313020902756279.

PMID:
19291534
15.

AGR2 expression in ovarian tumours: a potential biomarker for endometrioid and mucinous differentiation.

Armes JE, Davies CM, Wallace S, Taheri T, Perrin LC, Autelitano DJ.

Pathology. 2013 Jan;45(1):49-54. doi: 10.1097/PAT.0b013e32835bd561.

PMID:
23222243
16.

Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.

Kelly PJ, Archbold P, Price JH, Cardwell C, McCluggage WG.

J Clin Pathol. 2010 Feb;63(2):169-73. doi: 10.1136/jcp.2009.072355.

PMID:
20154039
17.

Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.

Zagorianakou N, Stefanou D, Makrydimas G, Zagorianakou P, Briasoulis E, Karavasilis V, Pavlidis N, Agnantis NJ.

Histol Histopathol. 2006 Apr;21(4):341-7.

PMID:
16437378
18.

Down-regulation of 8-hydroxydeoxyguanosine and peroxiredoxin II in the pathogenesis of endometriosis-associated ovarian cancer.

Sova H, Kangas J, Puistola U, Santala M, Liakka A, Karihtala P.

Anticancer Res. 2012 Aug;32(8):3037-44.

PMID:
22843871
19.

Expression of heparanase, Mdm2, and erbB2 in ovarian cancer.

Ginath S, Menczer J, Friedmann Y, Aingorn H, Aviv A, Tajima K, Dantes A, Glezerman M, Vlodavsky I, Amsterdam A.

Int J Oncol. 2001 Jun;18(6):1133-44.

PMID:
11351242
20.

Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis.

Scott M, McCluggage WG, Hillan KJ, Hall PA, Russell SE.

Int J Cancer. 2006 Mar 1;118(5):1325-9.

PMID:
16161048
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk